Compare BK & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BK | ZTS |
|---|---|---|
| Founded | 1784 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3B | 66.2B |
| IPO Year | N/A | 2013 |
| Metric | BK | ZTS |
|---|---|---|
| Price | $115.69 | $122.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | $113.23 | ★ $174.60 |
| AVG Volume (30 Days) | 3.5M | ★ 6.2M |
| Earning Date | 01-13-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.85% | 1.73% |
| EPS Growth | ★ 55.82 | 11.64 |
| EPS | ★ 6.93 | 5.94 |
| Revenue | ★ $19,734,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | $10.99 | $3.11 |
| Revenue Next Year | $3.93 | $5.14 |
| P/E Ratio | ★ $16.52 | $20.68 |
| Revenue Growth | ★ 9.66 | 2.68 |
| 52 Week Low | $70.46 | $115.25 |
| 52 Week High | $119.40 | $177.40 |
| Indicator | BK | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 48.32 |
| Support Level | $113.45 | $122.00 |
| Resistance Level | $119.40 | $125.53 |
| Average True Range (ATR) | 1.97 | 3.14 |
| MACD | -0.16 | 0.94 |
| Stochastic Oscillator | 48.75 | 68.11 |
Bank of New York Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors, delivering investment management and services in 35 countries and more than 100 markets. BNY is the largest global custody bank in the world, with $52.1 trillion in under custody or administration (as of December 2024), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY's asset-management division manages about $2.0 trillion in assets.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.